Skip to main content
. Author manuscript; available in PMC: 2017 Sep 6.
Published in final edited form as: Leukemia. 2016 Dec 26;31(9):1872–1881. doi: 10.1038/leu.2016.382

Figure 5.

Figure 5

Effect of oral duvelisib therapy on expression of BCL-2 family proteins in CLL lymphocytes before therapy (C1D1) and after 28 days (C2D1) of oral duvelisib intake. (A and B) Immunoblots of expression level of BCL2, Bim, Puma, and Bax proteins in CLL cells from patients before and after 28 days of oral duvelisib intake (n=15). Actin was used as normalization protein. These proteins were selected based on their changes as determined by the RPPA assay, available antibodies, and availability of amount of CLL samples. (C) Quantitation of these blots for all the patient samples analyzed (n=16). Statistical analyses were conducted to obtain p values that are included in the text.